The panel will focus on uses of ‘artificial intelligence and machine learning’ for cancer early detection, diagnosis, drug development and clinical decision making. These technologies have the potential to accelerate our understanding of cancer at the cellular and the systems (‘whole person’) level. The AI healthcare market is estimated to be $2.1 billion today and to grow to over $30 billion by 2025. To support such growth, the biopharma industry is rapidly expanding their human capital in this area through multiple means. Advances in machine learning are improving analysis of radiological images for cancer detection, as well as analysis of pathology slides and blood samples for cancer diagnosis and prognosis. In addition, artificial intelligence and machine learning are being deployed to aid in the discovery of novel therapies, optimize patient selection for treatment and monitor for drug resistance and disease recurrence. Although the potential impact of artificial intelligence in the oncology space is great, the panel will also explore challenges and obstacles that may delay widespread application.
The session will be moderated by Marc Hulbert, Chief Science Officer, Melanoma Research Alliance. Other panelists include:
- Mike Nohaile, Senior Vice President of Strategy, Commercialization and Innovation, Amgen
- Maurice Ferré, CEO and Chairman of the Board, INSIGHTEC
- Susan Swetter, Professor of Dermatology and Director of the Pigmented Lesion and Melanoma Program, Stanford University Medical Center and Cancer Institute
The Milken Institute is a nonprofit, nonpartisan think tank determined to increase global prosperity by advancing collaborative solutions that widen access to capital, create jobs and improve health through independent, data-driven research.